Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 246

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 246
---
 consultants and directors, and encourages them to devote their best efforts to its business and financial success. The principal features of its equity incentive plans are summarized below. The summaries are qualified in their entirety by reference to the actual text of the plans, which are filed as an exhibit to the registration statement of which this prospectus forms a part.

#### 2025 Equity Incentive Plan
At a special meeting in April 2025, Cara’s stockholders considered and approved the Company’s 2025 Equity Incentive Plan (the “2025 Plan”), which became effective at the closing of the Merger and following the Reverse Stock Split.

The purpose of the 2025 Plan is to provide a means whereby the Company can secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and its affiliates and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Company’s common stock through the granting of awards under the 2025 Plan.

Eligibility. Any individual who is an employee of the Company or any of its affiliates, or any person who provides services to the Company or its affiliates, including members of the Company’s board of directors, is eligible to receive awards under the 2025 Plan at the discretion of the plan administrator. All of the Company’s nonemployee directors, employees and consultants are eligible to receive awards under the 2025 Plan.

Awards. The 2025 Plan provides for the grant of incentive stock options (“ISOs”) to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, RSU awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates.

Authorized Shares. As of the Closing Date, there were 935,554 shares of the Company’s common stock available for grant under the 2025 Plan (the “Share Reserve”), subject to subject to adjustment for specified changes in the Company’s capitalization. In addition, the number of shares initially reserved and available for issuance under the 2025 Plan may be increased at the discretion of our board of directors (and without any further action by our stockholders) on January 1 of each year for a period of five years, commencing on January 1, 2026 and ending on January 1, 2030, in an amount